Methods for treating autoimmune diseases using a TACI-Ig fusion molecule
AssigneesZymoGenetics, Inc., Ares Trading S.A.
InventorsHerve Broly, Jennifer Visich, Ivan Nestorov, Sharon Busby, Jane Gross
Life of this patent
Estimating the term…
Abstract
In various embodiments, the present invention provides methods and compositions for treatment of autoimmune diseases, including rheumatoid arthritis, for example comprising administering to a patient in need of such treatment a TACI-Ig fusion molecule. In one embodiment, the TACI-Ig fusion molecule is administered in amount sufficient to slow, suppress or inhibit proliferation-inducing functions of BlyS and APRIL.
Claims17
A method for treatment of rheumatoid arthritis in a human patient comprising administering to the patient a composition comprising a fusion molecule selected from the group consisting of:
- (a) a fusion molecule comprising
- (i) TACI extracellular domain wherein said TACI extracellular domain is at least 95% identical to SEQ ID NO:1 and binds BlyS;
- and
- (ii) a human immunoglobulin-constant domain;
- (b) a fusion molecule comprising amino acids 30-110 of SEQ ID NO:
- 1 and a human immunoglobulin-constant domain;
- (c) a fusion molecule consisting of amino acids 30-110 of SEQ ID NO:
- 1 and a human immunoglobulin-constant domain;
- (d) a fusion molecule consisting of SEQ ID NO:
- 2;
- and
- (e) a fusion molecule consisting of amino acids 30-110 of SEQ ID NO:1 and the human immunoglobulin-constant domain of SEQ ID NO:
- 2;
- wherein said composition is administered in an amount from 1.0 mg per 1 kg of patient's body weight to 9.0 mg per 1 kg of patient's body weight and wherein said composition is administered in said amount 7 times during a twelve-week interval, 3 times during a four-week interval or every other week for 2 to 30 weeks.
A method for treatment of rheumatoid arthritis in a human patient comprising administering to the patient a composition comprising a fusion molecule selected from the group consisting of:
- (a) a fusion molecule comprising amino acids 30-110 of SEQ ID NO:
- 1 and a human immunoglobulin-constant domain;
- (b) a fusion molecule consisting of amino acids 30-110 of SEQ ID NO:
- 1 and a human immunoglobulin-constant domain;
- and
- (c) a fusion molecule consisting of SEQ ID NO:
- 2;
- wherein said composition is administered in an amount from 1.0 mg per 1 kg of patient's body weight to 9.0 mg per 1 kg of patient's body weight and wherein said composition is administered in said amount 7 times during a twelve-week interval, 3 times during a four-week interval or every other week for 2 to 30 weeks.
Dependencies are inferred from the claim text.